ERBB2 and breast cancer: Recently, Murthy et al. reported the results of a phase 2 TBCRC049 trial focused on 17 patients with LM from HER2-positive BC, who were treated with tucatinib, trastuzumab, and capecitabine: an i-PFS of 6.9 months (95% CI 2.3–13.8) and an OS of 10 months (95% CI 4.1-not reached) were observed [39].